ATLANTA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether REGENXBIO Inc. (“REGENXBIO” or the “Company”) (NASDAQ: RGNX) complied with federal securities laws. On January 28, 2026, REGENXBIO announced it “received communication from the U.S. Food and Drug Administration (“FDA”) that the Company’s Investigational New Drug applications for both its Phase I/II trial evaluating RGX-111 for Mucopolysaccharidosis type I and its Phase I/II/III trial of RGX-121 for Mucopolysaccharidosis ...

Core Viewpoint - Wealthfront Corporation is under investigation for potential violations of federal securities laws, particularly concerning misleading statements made during its IPO process [1][3]. Group 1: Company Overview - Wealthfront is an online financial advisor that utilizes automated tools to provide investment and financial advice [2]. - The company completed its initial public offering (IPO) on December 12, 2025, offering over 34 million shares at a price of $14.00 per share [2]. Group 2: Financial Performance - On January 12, 2026, Wealthfront reported its first quarterly results as a public company, revealing net deposit outflows of $208 million, a significant decline from the $874 million inflows during the same period the previous year [4]. - CEO David Fortunato attributed the decline in deposits to falling interest rates and highlighted the strategic importance of Wealthfront's new home-lending business [4]. Group 3: Stock Market Reaction - Following the earnings report, Wealthfront's stock price dropped by $2.12 per share, nearly 17%, from a closing price of $12.59 on January 12, 2026, to $10.47 on January 13, 2026 [4].

Core Viewpoint - Aquestive Therapeutics, Inc. is under investigation for potential violations of federal securities laws following an FDA letter identifying deficiencies in its NDA application for Anaphylm, impacting its market commitments and labeling discussions [1]. Company Summary - On January 9, 2026, Aquestive announced it received a letter from the FDA regarding deficiencies in its NDA application for Anaphylm, which is intended for the emergency treatment of anaphylaxis [1]. - Following this announcement, Aquestive's stock price dropped by $2.18, representing a 35.1% decline, opening at $4.03 [2]. Legal Context - Levi & Korsinsky LLP has initiated an investigation into Aquestive Therapeutics, focusing on potential recovery options for investors who may have suffered losses due to the recent developments [2]. - The firm has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [3].

Core Viewpoint - Mereo BioPharma Group plc is under investigation for potential violations of federal securities laws following disappointing clinical trial results that led to a significant drop in stock price [1][2]. Group 1: Company Performance - On December 29, 2025, Mereo BioPharma announced results from its Phase 3 ORBIT and COSMIC studies for setrusumab (UX143) in Osteogenesis Imperfecta (OI), reporting that neither study achieved its primary efficacy endpoint of reducing the annualized clinical fracture rate compared to placebo [2]. - Following the announcement, Mereo's stock price plummeted over 89%, opening at $0.25 per share [2]. Group 2: Legal Investigation - Levi & Korsinsky has commenced an investigation into Mereo BioPharma Group plc concerning potential violations of federal securities laws, inviting investors who suffered losses to explore recovery options [1][3].

Core Viewpoint - BellRing Brands, Inc. is under investigation for potential violations of federal securities laws, with concerns regarding the sustainability of its sales growth driven by temporary trade inventory loading rather than genuine consumer demand [1][2]. Group 1: Company Overview - BellRing Brands operates in the convenient nutrition category, primarily known for its brands Premier Protein and Dymatize, which offer ready-to-drink protein shakes and powders [2]. - The company reported that Premier Protein achieved an all-time high in household penetration, with strong demand and growth across all channels attributed to distribution expansion and promotional activities [2]. Group 2: Sales Growth Concerns - The sales growth during the relevant period may not be sustainable, as it could have been influenced by temporary inventory loading at key retailers rather than lasting consumer demand [2]. - On May 5, 2025, BellRing disclosed that several key retailers reduced their weeks of supply on hand, which would negatively impact growth in Q3 2025 [3]. Group 3: Stock Performance - Following the announcement on May 5, 2025, BellRing's stock price dropped by $13.96, or over 18%, from $77.34 to $63.38 per share [3]. - On August 4, 2025, the company reported disappointing quarterly consumption of Premier Protein RTD Shakes, leading to a further decline in stock price by $17.46, or nearly 33%, from $53.64 to $36.18 per share [4].

Core Viewpoint - Ardent Health, Inc. is under investigation for potential violations of federal securities laws due to improper accounting practices related to accounts receivable and professional liability reserves [1][2]. Financial Performance - In Q3 2025, Ardent reported a $43 million decrease in revenue after conducting evaluations of historical collection trends [3]. - The company increased its professional liability reserves by $54 million due to adverse developments from claims between 2019 and 2022, as well as broader industry trends [3]. Stock Market Reaction - Following the financial report on November 12, 2025, Ardent's stock price dropped over 33% during trading on November 13, 2025 [3].

Core Viewpoint - Coty Inc. is under investigation for potential violations of federal securities laws, following disappointing financial results and claims of overstated demand for its Prestige fragrances [1][2][3]. Group 1: Company Overview - Coty Inc. is one of the largest beauty companies globally, with a diverse portfolio that includes fragrance, color cosmetics, and skin and body care products [2]. - Prestige fragrances represent 60% of Coty's revenues, indicating a significant reliance on this segment [2]. Group 2: Financial Performance - On August 20, 2025, Coty reported disappointing financial results for Q4 and FY 2025, citing issues such as retailer inventory buildup and execution weaknesses in the U.S. market [3]. - The company's stock price fell from $4.86 to $3.81 per share, a decline of over 21%, following the release of these results [3]. Group 3: Market Dynamics - Coty indicated that retailers were maintaining tight inventory levels, while in reality, they were overstocked due to a decline in demand for Coty's products [2]. - The company faced challenges in the cosmetics sector attributed to value-seeking consumer behavior, innovation fatigue, and specific U.S. market factors [3].

Core Insights - Sonic Automotive, Inc. is under investigation for possible violations of federal securities laws, as announced by Levi & Korsinsky [1] - The company reported a 33% decline in net income for Q3 2025, attributed to increased medical expenses and a higher effective income tax rate [2] - Following the financial results announcement, Sonic Automotive's stock price dropped over 15% on the same day [2] Company Financial Performance - Sonic Automotive's net income decreased by 33% in Q3 2025 [2] - The decline in net income was primarily due to significant increases in medical expenses and a higher effective income tax rate [2] Stock Market Reaction - The stock price of Sonic Automotive fell by more than 15% on October 23, 2025, immediately after the financial results were released [2]

Core Viewpoint - Replimune Group, Inc. is under investigation for potential violations of federal securities laws following a significant decline in its stock price after receiving a Complete Response Letter from the FDA regarding its lead product RP1 [1][3]. Company Summary - Replimune received a Complete Response Letter from the FDA on July 22, 2025, indicating that its IGNYTE trial was not considered adequate for demonstrating the effectiveness of RP1 in combination with nivolumab for advanced melanoma [3]. - Following the FDA's announcement, Replimune's stock price fell by $9.52, or approximately 77.24%, closing at $2.81 per share [3]. Legal Investigation Summary - Kirby McInerney LLP is investigating potential claims against Replimune and its officers for possible violations of federal securities laws and other unlawful business practices [1][4].